Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis

PLoS Genetics

Volumn 6, Issue 6, 2010, Pages 1-9

  Francis, Jeffrey C ^a   McCarthy, Afshan ^a   Thomsen, Martin K ^a   Ashworth, Alan ^a   Swain, Amanda ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BRCA2 PROTEIN; PROTEIN P53; BRCA2 PROTEIN, MOUSE; TP53 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; GENETIC ANALYSIS; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; TUMOR SUPPRESSOR GENE; ANIMAL; CELL TRANSFORMATION; DISEASE COURSE; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROSTATE TUMOR;

ANIMALIA;

ANIMALS; APOPTOSIS; BRCA2 PROTEIN; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; DNA DAMAGE; MALE; MICE; MICE, KNOCKOUT; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954162660     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1000995     Document Type: Article

References (56)

1. Bostwick DG, Liu L, Brawer MK, Qian J (2004) High-grade prostatic intraepithelial neoplasia. Rev Urol 6: 171-179
2. Eeles RA (1999) Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 2: 9-15
3. Ostrander EA, Stanford JL (2000) Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 67: 1367-1375
4. Anderson DE, Badzioch MD (1993) Familial effects of prostate and other cancers on lifetime breast cancer risk. Breast Cancer Res Treat 28: 107-113
5. Thiessen EU (1974) Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer 34: 1102-1107
6. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H (1992) Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 305: 855-857
7. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H (1999) Cancer risks in BRCA2 mutation carriers.The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91: 1310-1316
8. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, et al. (1999) Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 35: 1248-1257
9. Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, et al. (2002) The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 39: 457-462
10. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, et al. (2005) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42: 711-719
11. Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, et al. (2007) Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 97: 826-831
12. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, et al. (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72: 1-12
13. Agalliu I, Gern R, Leanza S, Burk RD (2009) Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 15: 1112-1120
14. Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, et al. (2008) Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 98: 502-507
15. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT, et al. (2008) Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 99: 371-374
16. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T, Jonasson JG, Olafsdottir EJ, et al. (2007) Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 99: 929-935
17. Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25: 5864-5874
18. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, et al. (1997) Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386: 804-810
19. Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, et al. (2001) Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J 20: 4704-4716
20. Kraakman-vander Zwet M, Overkamp WJ, van Lange RE, Essers J, van Duijn- Goedhart A, et al. (2002) Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 22: 669-679
21. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, et al. (1998) Involvement of Brca2 in DNA repair. Mol Cell 1: 347-357
22. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A (1997) Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11: 1226-1241
23. Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, et al. (1997) Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11: 1242-1252
24. Cheung AM, Elia A, Tsao MS, Done S, Wagner KU, et al. (2004) Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice. Cancer Res 64: 1959-1965
25. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, et al. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425
26. Ludwig T, Fisher P, Murty V, Efstratiadis A (2001) Development of mammary adenocarcinomas by tissue-specific knockout of Brca2 in mice. Oncogene 20: 3937-3948
27. Wu X, Wu J, Huang J, Powell WC, Zhang J, et al. (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101: 61-69
28. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4: 209-221
29. Bruxvoort KJ, Charbonneau HM, Giambernardi TA, Goolsby JC, Qian CN, et al. (2007) Inactivation of Apc in the mouse prostate causes prostate carcinoma. Cancer Res 67: 2490-2496
30. Pearson HB, Phesse TJ, Clarke AR (2009) K-ras and Wnt signaling synergize to accelerate prostate tumorigenesis in the mouse. Cancer Res 69: 94-101
31. Hay T, Patrick T, Winton D, Sansom OJ, Clarke AR (2005) Brca2 deficiency in the murine small intestine sensitizes to p53-dependent apoptosis and leads to the spontaneous deletion of stem cells. Oncogene 24: 3842-3846
32. Frappart PO, Lee Y, Lamont J, McKinnon PJ (2007) BRCA2 is required for neurogenesis and suppression of medulloblastoma. EMBO J 26: 2732-2742.
33. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double- stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868
34. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, et al. (2009) Ki- 67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 100: 888-893
35. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261
36. Hudson DL (2004) Epithelial stem cells in human prostate growth and disease. Prostate Cancer Prostatic Dis 7: 188-194
37. Hallstrom TM, Laiho M (2008) Genetic changes and DNA damage responses in the prostate. Prostate 68: 902-918
38. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
39. Mitra A, Jameson C, Barbachano Y, Sodha Z, Kote-Jarai N, et al. (2009) Overexpression of TP53 is Associated with Aggressive Prostate Cancer but does not Distinguish Disease in BRCA1 or BRCA2 Mutation Carriers from a Control Group. The Open Prostate Cancer Journal 2: 38-45
40. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, et al. (2009) High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69: 3625-3633
41. Cheung AM, Hande MP, Jalali F, Tsao MS, Skinnider B, et al. (2002) Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. Cancer Res 62: 6194-6204
42. Norbury CJ, Zhivotovsky B (2004) DNA damage-induced apoptosis. Oncogene 23: 2797-2808
43. Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276-308
44. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, et al. (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 103: 1480-1485
45. Korsten H, Ziel-vander M.A, Ma X, van der Kwast T, Trapman J (2009) Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS ONE 4: e5662. doi:10.1371/journal.pone.0005662.
46. Schalken JA, van Leenders G (2003) Cellular and molecular biology of the prostate: stem cell biology. Urology 62: 11-20
47. Isaacs W, De Marzo A, Nelson WG (2002) Focus on prostate cancer. Cancer Cell 2: 113-116
48. Freeman D, Lesche R, Kertesz N, Wang S, Li G, et al. (2006) Genetic background controls tumor development in PTEN-deficient mice. Cancer Res 66: 6492-6496
49. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumori- genesis. Nature 436: 725-730
50. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, et al. (2002) Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 62: 2999-3004
51. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, et al. (2002) Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 22: 1495-1503
52. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921
53. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134.
54. Park JH, Walls JE, Galvez JJ, Kim M, Abate-Shen C, et al. (2002) Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol 161:727-735.
55. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, et al. (2004) Prostate pathology of genetically engineered mice: definitions and classification.The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64:2270-2305.
56. Thomsen MK, Butler CM, Shen MM, Swain A (2008) Sox9 is required for prostate development. Dev Biol 316: 302-311.